( GAITHERSBURG Md. March 21 2007--Med...)Research Results on FluMist Presented at National Association of,Pediatric Nurse Practitioners Conference,Health

GAITHERSBURG, Md., March 21, 2007--MedImmune, Inc. (Nasdaq: MEDI) announced today that researchers will present data from three key studies involving the nasal-spray flu vaccine FluMist(R) (Influenza Virus Vaccine Live, Intranasal) during the National Association of Pediatric Nurse Practitioners' (NAPNAP) 28th Annual Conference on Pediatric Health Care in Lake Buena Vista, Florida. Results of two of the studies indicate that school-based influenza vaccination programs may represent an effective and feasible approach to help reduce influenza infection rates among vaccinated children and may also prove to be a valuable model to vaccinate large groups quickly. A third study of nearly 8,500 children six months to 5 years of age found that children vaccinated with FluMist experienced 55 percent fewer cases of influenza compared to those who received the flu shot. FluMist is currently indicated for healthy children and adolescents 5 to 17 years of age and healthy adults 18 to 49 years of age. Based on the results of this pivotal Phase 3 study, MedImmune has filed with the U. S. Food & Drug Administration (FDA) for an expanded indication for FluMist to include children as young as one year of age without a history of wheezing or asthma.

Studies to be presented at the conference, which will be held here March 21-24, include:

-- Effectiveness of a School-Based Influenza Vaccination Intervention
(Podium session presentation, "115: Clinical Papers," presented on
Wednesday, March 21 by Ginny Cummings, MS, CRNP, Clinical Research
Coordinator at the University of Maryland School of Medicine)

-- Implementing a Mass Influenza Vaccination Program: The Carroll County
Experience (Poster session presentation on March 21-23 by Brigit
VanGraafeiland, MS, CRNP, of the University of Maryland School of
Nursing)

-- C
'"/>